Investigating how ponatinib affects heart cells and causes heart problems in cancer treatment.
Official title: Mitochondrial Dysfunction Underlies the Integrated Stress Response Activation in Ponatinib-Induced Cardiotoxicity
Funded at University of Arizona · NIH-10890168 · Data updated 2026-11-12
This study is looking at how the cancer drug ponatinib affects heart cells in people with chronic myeloid leukemia, hoping to find ways to protect the heart from any harmful side effects while treating cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | July 18, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $529,969 |
| NIH project number | 5R01HL164729-02 |
| Project ID | NIH-10890168 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adult patients with chronic myeloid leukemia who are being treated with ponatinib.
✕Less likely to help
Patients who are not receiving ponatinib or those with pre-existing severe heart conditions may not benefit from this research.
What this research studies
This research focuses on understanding the effects of ponatinib, a medication used to treat chronic myeloid leukemia, on heart cells. It aims to explore the mechanisms behind cardiotoxicity, which is a harmful side effect that can occur with this treatment. By examining how heart cells respond to stress and the integrated stress response activation, the study seeks to identify potential new therapies to protect the heart during cancer treatment. Patients may benefit from insights that could lead to safer cancer therapies with fewer cardiac complications.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that minimize heart damage in cancer patients receiving ponatinib.
How similar studies have gone: Previous research has shown that understanding cellular responses to cancer therapies can lead to significant advancements in mitigating side effects, suggesting potential success for this approach.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Lee, Won Hee — University of Arizona
- Study coordinator: Lee, Won Hee
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
High-throughput 3D human heart tissue to screen drug safety
A Johns Hopkins team is creating a high-throughput, 3D human heart tissue model to test drug safety on human heart cells.
-
Precision imaging of heart damage from cancer treatment using metabolic MRI biomarkers
Researchers will use advanced MRI to find early metabolic signs of heart injury in cancer patients treated with common drugs, so doctors can protect the heart earlier.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.